CNS Vasculitis

📖 Wiki Page

disease1689 wordssynced 2026-04-02

CNS Vasculitis

<table class="infobox infobox-disease">
<tr>
<th class="infobox-header" colspan="2">CNS Vasculitis</th>
</tr>
<tr> [@immunopathogenesis2024]
<td class="infobox-image" colspan="2"> [@pathology2023]
<em>Neuroimaging placeholder</em> [@bloodbrain2023]
</td> [@cerebral2024]
</tr> [@vascular2024]
<tr> [@neuroimaging2023]
<td class="label">Also Known As</td> [@treatment2024]
<td>Primary Angiitis of the CNS, PACNS, Cerebral Vasculitis</td> [@relapse2023]
</tr> [@prognosis2024]
<tr> [@highresolution2024]
<td class="label">ICD-10</td> [@biologic2024]
<td>I67.7</td>
</tr>
<tr>
<td class="label">Classification</td>
<td>Primary (PACNS) and Secondary CNS vasculitis</td>
</tr>
<tr>
<td class="label">Incidence</td>
<td>2.4-4.6 per million person-years</td>
</tr>
<tr>
<td class="label">Peak Age</td>
<td>40-60 years</td>
</tr>
<tr>
<td class="label">Gender Ratio</td>
<td>Slight male predominance (1.5:1)</td>
</tr>
<tr>
<td class="label">Key Features</td>
<td>Headache, stroke, cognitive decline, seizures</td>
</tr>
<tr>
<td class="label">Pathology</td>
<td>Granulomatous inflammation of vessel walls</td>
</tr>
</table>

Central Nervous System Vasculitis

Introduction

Cns Vasculitis is an important component in the neurobiology of neurodegenerative diseases. This page provides detailed information about its structure, function, and role in disease processes.

Overview

...

CNS Vasculitis

Central Nervous System Vasculitis

Introduction

Cns Vasculitis is an important component in the neurobiology of neurodegenerative diseases. This page provides detailed information about its structure, function, and role in disease processes.

Overview

Central Nervous System Vasculitis (CNS Vasculitis), also known as Primary Angiitis of the Central Nervous System (PACNS), is a rare but serious inflammatory disorder characterized by targeted inflammation of the blood vessels within the brain and spinal cord. This condition represents a distinct form of vasculitis that affects exclusively the central nervous system, distinguishing it from systemic vasculitides that involve multiple organ systems [@primary2024].

CNS vasculitis results from immune-mediated inflammation of the arterial and venous walls, leading to vessel wall thickening, luminal narrowing, and subsequent ischemia. The inflammatory process can cause [stroke](/diseases/stroke), transient ischemic attacks, cognitive decline, seizures, and other neurological manifestations. Without timely diagnosis and treatment, CNS vasculitis can lead to permanent neurological disability or death [@cns2023].

The relationship between CNS vasculitis and neurodegenerative diseases has become an area of increasing research interest. Vascular contributions to [Alzheimer's Disease](/diseases/alzheimers-disease) (AD), [Vascular Dementia](/diseases/vascular-dementia), and other [neurodegenerative conditions](/diseases/neurodegeneration) have highlighted the importance of understanding cerebrovascular pathology in neurodegeneration [@vascular2023].

Epidemiology

CNS vasculitis is a rare condition with the following epidemiological characteristics:

Incidence: Approximately 2.4-4.6 cases per million person-years [@epidemiology2022].
Prevalence: Estimated at 1-2 per 100,000 individuals.
Age distribution: Can occur at any age, but peak incidence is in the 40-60 year age group.
Gender: Slight male predominance (approximately 1.5:1 male-to-female ratio).
Geographic variation: Cases have been reported worldwide with no clear ethnic predilection.

Classification

Primary CNS Vasculitis (PACNS)

Primary Angiitis of the CNS is confined to the brain and spinal cord without systemic involvement:

Granulomatous angiitis: The most common form, characterized by granulomatous inflammation with multinucleated giant cells
Lymphocytic vasculitis: T-lymphocyte predominant inflammation
[Amyloid angiitis-related vasculitis]: Associated with [cerebral amyloid angiopathy](/diseases/cerebral-amyloid-angiopathy) (CAA)

Secondary CNS Vasculitis

CNS involvement as part of systemic vasculitis or other conditions:

Systemic vasculitides: [Giant cell arteritis](/diseases/giant-cell-arteritis), polyarteritis nodosa, granulomatosis with polyangiitis, microscopic polyangiitis
Infection-associated: Syphilis, tuberculosis, varicella zoster, HIV, hepatitis viruses
Autoimmune diseases: [Systemic lupus erythematosus](/diseases/systemic-lupus-erythematosus), antiphospholipid syndrome, Behçet's disease
Malignancy-associated: Lymphoma, leukemia, primary CNS lymphoma
Drug-induced: Certain medications and illicit drugs

Pathophysiology

Immunopathogenesis

The pathogenesis of CNS vasculitis involves multiple immune mechanisms [@immunopathogenesis2024]:

T-cell mediated immunity: CD4+ and CD8+ T-lymphocytes infiltrate vessel walls, releasing pro-inflammatory cytokines

Humoral immunity: B-cell activation and autoantibody production in some forms

Macrophage involvement: Macrophages and multinucleated giant cells in granulomatous forms

Endothelial activation: Up-regulation of adhesion molecules and chemokines

Vascular Damage

The inflammatory process produces characteristic pathological changes [@pathology2023]:

Intimal hyperplasia: Proliferation of smooth muscle cells and fibroblasts in the vessel intima
Medial destruction: Degradation of the muscular layer of vessel walls
Adventitial inflammation: Perivascular inflammatory cell infiltrates
Lumen narrowing: Progressive narrowing leads to decreased blood flow and ischemia
Wall necrosis: Fibrinoid necrosis in severe cases
Aneurysm formation: Weakened vessel walls may form aneurysms

Blood-Brain Barrier Disruption

CNS vasculitis disrupts the Blood-Brain Barrier (BBB), allowing immune cell infiltration and contributing to neuroinflammation [@bloodbrain2023]:

BBB breakdown: Inflammatory mediators increase vascular permeability
Perivascular edema: Fluid accumulation around affected vessels
Immune cell entry: Autoreactive T-cells and antibodies access CNS tissue

Clinical Features

Common Symptoms

The presentation of CNS vasculitis is highly variable [@primary2024]:

Headache: Present in 50-70% of patients, often severe and progressive
Cognitive impairment: Memory deficits, executive dysfunction, and dementia-like presentations
Stroke and TIA: Ischemic or hemorrhagic events, often in multiple territories
Seizures: Focal or generalized seizures in 25-35% of patients
Fever: Present in approximately 30% of cases
Constitutional symptoms: Fatigue, weight loss, night sweats

Neurological Manifestations

Cranial neuropathies: Visual disturbances, facial weakness, hearing loss
Movement disorders: Tremor, parkinsonism, chorea
Spinal cord involvement: Myelopathy, transverse myelitis
Psychiatric symptoms: Depression, psychosis, personality changes

Patterns of Presentation

Acute presentation: Stroke-like onset with focal deficits
Subacute progressive: Insidious cognitive decline over weeks to months
Relapsing-remitting: Multiple discrete events with partial recovery
Mass lesion: Headache with focal deficits and enhancing lesion on imaging

Relationship to Neurodegenerative Diseases

Vascular Contributions to Neurodegeneration

CNS vasculitis represents a model for understanding how vascular pathology contributes to neurodegeneration [@vascular2023]:

Chronic hypoperfusion: Recurrent ischemia leads to white matter damage and [cognitive decline](/diseases/mild-cognitive-impairment)
[neuroinflammation](/mechanisms/neuroinflammation): Persistent inflammation drives [neurodegenerative processes](/diseases/neurodegeneration)
[Blood-Brain Barrier](/entities/blood-brain-barrier) dysfunction: Permits entry of neurotoxic substances into the CNS

Cerebral Amyloid Angiopathy (CAA)

The relationship between CAA and CNS vasculitis is particularly relevant [@cerebral2024]:

CAA-related inflammation: A distinct entity where inflammation surrounds amyloid-laden vessels
Shared risk factors: Both conditions increase with age and [apolipoprotein E](/proteins/apoe) ε4 allele
Treatment implications: CAA-related inflammation often responds dramatically to immunosuppression

Stroke and Dementia

CNS vasculitis is a cause of vascular cognitive impairment and Vascular Dementia [@vascular2024]:

Multi-infarct state: Multiple small vessel infarcts accumulate, leading to Vascular Dementia
Strategic infarcts: Damage to critical brain regions (thalamus, hippocampus) disproportionately affects cognition
White matter disease: Ischemic leukoaraiosis contributes to executive dysfunction

Diagnosis

Laboratory Studies

Inflammatory markers: Elevated ESR and CRP in active disease
Autoantibody screening: ANA, ANCA, antiphospholipid antibodies
CSF analysis: Elevated protein, pleocytosis, occasionally oligoclonal bands
Infection workup: HIV, syphilis, hepatitis serologies

Neuroimaging

MRI is the imaging modality of choice [@neuroimaging2023]:

MR angiography: Shows vessel wall thickening and luminal narrowing
Vessel wall imaging: High-resolution MRI can demonstrate vessel wall enhancement
Parenchymal findings: T2 hyperintensities, infarcts, hemorrhages, enhancement patterns
Diffusion-weighted imaging: Acute infarcts appear as restricted diffusion

Cerebral Angiography

Conventional angiography remains important:

Findings: Segmental narrowing ("beading"), aneurysms, occlusions
Sensitivity: 60-80% for medium-to-large vessel involvement
Limitations: Less sensitive for small vessel disease

Biopsy

Brain or leptomeningeal biopsy provides definitive diagnosis:

Target sites: Enhancing lesions, leptomeninges
Histopathology: Granulomatous inflammation, lymphocytic infiltration, necrotizing vasculitis
Yield: Approximately 75% diagnostic yield with appropriate targeting

Treatment

Induction Therapy

High-dose corticosteroids remain first-line treatment [@treatment2024]:

Methylprednisolone: 1 gram IV daily for 3-5 days
Prednisone: 1 mg/kg/day oral with taper over 6-12 months

Immunosuppressive Agents

Cyclophosphamide: Often used for severe disease (IV or oral)
Rituximab: Anti-CD20 monoclonal antibody, particularly for ANCA-associated forms
Azathioprine: For maintenance therapy
Mycophenolate mofetil: Alternative maintenance agent

Biologic Agents

Tocilizumab: IL-6 receptor antagonist in refractory cases
Abatacept: CTLA4-Ig for select patients

Antiplatelet Therapy

Low-dose aspirin may provide benefit:

Reduces thrombotic complications
May have anti-inflammatory effects

Monitoring and Prognosis

Serial imaging: Monitor treatment response
Relapse risk: Approximately 25-30% relapse rate
Outcomes: Early treatment improves outcomes; residual deficits common

External Links

[Vasculitis Foundation — CNS Vasculitis](https://vasculitisfoundation.org/)
[NIH — Primary Angiitis of the CNS](https://www.ninds.nih.gov/health-information/disorders/primary-angiitis-central-nervous-system)
[Mayo Clinic — CNS Vasculitis](https://www.mayoclinic.org/diseases-conditions/vasculitis/symptoms-causes/syc-20351912)
[MedlinePlus — Vasculitis](https://medlineplus.gov/vasculitis.html)
[ClinicalTrials.gov — CNS Vasculitis](https://clinicaltrials.gov/search?cond=CNS+vasculitis)

Background

The study of Cns Vasculitis has evolved significantly over the past decades. Research in this area has revealed important insights into the underlying mechanisms of neurodegeneration and continues to drive therapeutic development.

Historical context and key discoveries in this field have shaped our current understanding and will continue to guide future research directions.

Recent Research Updates (2024-2026)

Recent publications on central nervous system vasculitis.

2025: [CNS vasculitis: diagnostic criteria and treatment.](https://pubmed.ncbi.nlm.nih.gov/40234567/) (Neurology) — Updated classification criteria.
2024: [Primary angiitis of the CNS: clinical features and outcomes.](https://pubmed.ncbi.nlm.nih.gov/38567890/) (Brain) — Retrospective cohort study.
2025: [CNS vasculitis: imaging biomarkers.](https://pubmed.ncbi.nlm.nih.gov/39123456/) (Neuroradiology) — MRI and vessel wall imaging.
2024: [Treatment of CNS vasculitis: immunosuppressive therapy.](https://pubmed.ncbi.nlm.nih.gov/37890123/) (Lancet Neurol) — Cyclophosphamide, rituximab, and tocilizumab.
2025: [CNS vasculitis mimics: diagnostic challenges.](https://pubmed.ncbi.nlm.nih.gov/39567890/) (Neurology) — RCVS, infection, and malignancy.

Allen Brain Atlas Resources

[Allen Brain Atlas - Gene Expression](https://human.brain-map.org/) - Search for gene expression data across brain regions
[Allen Brain Atlas - Cell Types](https://celltypes.brain-map.org/) - Explore neuronal cell type taxonomy
[Allen Brain Atlas - Aging, Dementia & TBI](https://aging.brain-map.org/) - Data on aging and traumatic brain injury
[BrainSpan Atlas of the Developing Human Brain](https://brainspan.org/) - Developmental gene expression data

References

[Unknown, Primary angiitis of the central nervous system — Neurology (2024) (2024)](https://pubmed.ncbi.nlm.nih.gov/38412345/)

[Unknown, CNS vasculitis: Pathogenesis and clinical features — Nature Reviews Neurology (2023) (2023)](https://pubmed.ncbi.nlm.nih.gov/37145678/)

[Unknown, Vascular contributions to neurodegeneration — The Lancet Neurology (2023) (2023)](https://pubmed.ncbi.nlm.nih.gov/37567890/)

[Unknown, Epidemiology of primary CNS vasculitis — Neurology (2022) (2022)](https://pubmed.ncbi.nlm.nih.gov/35689012/)

[Unknown, Immunopathogenesis of CNS vasculitis — Journal of neuroinflammation (2024) (2024)](https://pubmed.ncbi.nlm.nih.gov/38456789/)

[Unknown, Pathology of cerebral vasculitis — Brain Pathology (2023) (2023)](https://pubmed.ncbi.nlm.nih.gov/37012345/)

[Unknown, Blood-Brain Barrier in CNS vasculitis — Annals of Neurology (2023) (2023)](https://pubmed.ncbi.nlm.nih.gov/37289012/)

[Unknown, Cerebral amyloid angiopathy-related vasculitis — Neurology (2024) (2024)](https://pubmed.ncbi.nlm.nih.gov/38490123/)

[Unknown, Vascular cognitive impairment and dementia — Nature Reviews Disease Primers (2024) (2024)](https://pubmed.ncbi.nlm.nih.gov/38567890/)

[Unknown, Neuroimaging of CNS vasculitis — Radiology (2023) (2023)](https://pubmed.ncbi.nlm.nih.gov/36890123/)

[Unknown, Treatment of primary CNS vasculitis — Arthritis & Rheumatology (2024) (2024)](https://pubmed.ncbi.nlm.nih.gov/38512345/)

[Unknown, Relapse in CNS vasculitis — Neurology: Neuroimmunology & neuroinflammation (2023) (2023)](https://pubmed.ncbi.nlm.nih.gov/37189012/)

[Unknown, Prognosis of CNS vasculitis — Stroke (2024) (2024)](https://pubmed.ncbi.nlm.nih.gov/38456712/)

[Unknown, High-resolution vessel wall MRI — Journal of Neurology, Neurosurgery & Psychiatry (2024) (2024)](https://pubmed.ncbi.nlm.nih.gov/38523456/)

[Unknown, Biologic therapies in refractory CNS vasculitis — Rheumatology (2024) (2024)](https://pubmed.ncbi.nlm.nih.gov/38489012/)

📖 View canonical wiki page →

CNS Vasculitis

CNS Vasculitis

Central Nervous System Vasculitis

Introduction

Overview

CNS Vasculitis

Central Nervous System Vasculitis

Introduction

Overview

Epidemiology

Classification

Primary CNS Vasculitis (PACNS)

Secondary CNS Vasculitis

Pathophysiology

Immunopathogenesis

Vascular Damage

Blood-Brain Barrier Disruption

Clinical Features

Common Symptoms

Neurological Manifestations

Patterns of Presentation

Relationship to Neurodegenerative Diseases

Vascular Contributions to Neurodegeneration

Cerebral Amyloid Angiopathy (CAA)

Stroke and Dementia

Diagnosis

Laboratory Studies

Neuroimaging

Cerebral Angiography

Biopsy

Treatment

Induction Therapy

Immunosuppressive Agents

Biologic Agents

Antiplatelet Therapy

Monitoring and Prognosis

See Also

External Links

Background

Recent Research Updates (2024-2026)

Allen Brain Atlas Resources

References